Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Sponsor
Regeneron Pharmaceuticals (Industry)
Overall Status
Available
CT.gov ID
NCT05164250
Collaborator
(none)

Study Details

Study Description

Brief Summary

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

Condition or Disease Intervention/Treatment Phase

Detailed Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Study Design

Study Type:
Expanded Access

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    Exclusion Criteria:

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Regeneron Pharmaceuticals

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Regeneron Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT05164250
    Other Study ID Numbers:
    • R5458-MM
    First Posted:
    Dec 20, 2021
    Last Update Posted:
    Dec 20, 2021
    Last Verified:
    Dec 1, 2021
    Keywords provided by Regeneron Pharmaceuticals
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 20, 2021